Emerging treatment strategies for glioblastoma multiforme.
Emerging treatment strategies for glioblastoma multiforme.
复制标题
DOI：
10.15252/emmm.201302627
复制
发表时间：
2014-11
影响因子：
11.1
通讯作者：
Wahlestedt C
中科院分区：
文献类型：
--
作者：
Carlsson SK;Brothers SP;Wahlestedt C
多形性胶质母细胞瘤（GBM）是最致命的脑肿瘤，5年死亡率超过90%。GBM的中位生存期仅为12.6个月，这归因于独特的治疗局限性，如高平均发病年龄、肿瘤位置和目前对肿瘤病理生理学的理解不足。目前用于治疗GBM的切除技术、化疗策略和放射治疗已经缓慢发展，但这些改善并没有转化为患者生存率的显著增加。在这里，我们将讨论我们对GBM病理生理学的理解，以及诊断技术和治疗方案的最新进展。讨论将包括生物标志物，肿瘤成像，新的治疗方法，如单克隆抗体和小分子抑制剂，以及GBM癌症干细胞群的异质性。
Glioblastoma multiforme (GBM) is the deadliest form of brain tumor with a more than 90% 5-year mortality. GBM has a paltry median survival of 12.6 months attributed to the unique treatment limitations such as the high average age of onset, tumor location, and poor current understandings of the tumor pathophysiology. The resection techniques, chemotherapic strategies, and radiation therapy currently used to treat GBM have slowly evolved, but the improvements have not translated to marked increases in patient survival. Here, we will discuss the recent progress in our understanding of GBM pathophysiology, and the diagnostic techniques and treatment options. The discussion will include biomarkers, tumor imaging, novel therapies such as monoclonal antibodies and small-molecule inhibitors, and the heterogeneity resulting from the GBM cancer stem cell population.